VANDA PHARMACEUTICALS INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
VANDA PHARMACEUTICALS INC. (VNDA) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $283.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-15.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2018-02-15
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2015-12-31 was $1.00K.
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2015-09-30 was $0.00.
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2015-06-30 was $0.00.
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2015-03-31 was $282.00K, a 35.32% decline year-over-year.
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2015 was $283.00K, a 35.09% decline from fiscal 2014.
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2014 was $436.00K, a 122.45% increase from fiscal 2013.
- VANDA PHARMACEUTICALS INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2013 was $196.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2015-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $1.00K derived: sum of 2 quarters · filed 2018-02-15 | $1.00K derived: sum of 3 quarters · filed 2018-02-15 | $283.00K 10-K · filed 2018-02-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 derived: sum of 2 quarters · filed 2015-11-04 | $282.00K 10-Q · filed 2015-11-04 | $282.00K derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $282.00K 10-Q · filed 2015-07-31 | $282.00K derived: sum of 3 quarters · filed 2017-02-17 | $282.00K derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $282.00K 10-Q · filed 2015-05-07 | $282.00K derived: sum of 2 quarters · filed 2017-02-17 | $282.00K derived: sum of 3 quarters · filed 2017-02-17 | $282.00K derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $436.00K 10-K · filed 2017-02-17 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | $0.00 derived: sum of 2 quarters · filed 2014-10-27 | $436.00K 10-Q · filed 2014-10-27 | $436.00K derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $436.00K 10-Q · filed 2014-08-08 | $436.00K derived: sum of 3 quarters · filed 2016-02-12 | |
| 2014-03-31 | $436.00K 10-Q · filed 2014-05-08 | $436.00K derived: sum of 2 quarters · filed 2016-02-12 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $196.00K 10-K · filed 2016-02-12 | ||
| 2013-09-30 | $196.00K 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |